Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Acta Diabetologica
Published in: Acta Diabetologica 4/2009

Open Access 01-12-2009 | Review Article

Exercise therapy in Type 2 diabetes

Authors: Stephan F. E. Praet, Luc J. C. van Loon

Published in: Acta Diabetologica | Issue 4/2009

Login to get access

Abstract

Structured exercise is considered an important cornerstone to achieve good glycemic control and improve cardiovascular risk profile in Type 2 diabetes. Current clinical guidelines acknowledge the therapeutic strength of exercise intervention. This paper reviews the wide pathophysiological problems associated with Type 2 diabetes and discusses the benefits of exercise therapy on phenotype characteristics, glycemic control and cardiovascular risk profile in Type 2 diabetes patients. Based on the currently available literature, it is concluded that Type 2 diabetes patients should be stimulated to participate in specifically designed exercise intervention programs. More attention should be paid to cardiovascular and musculoskeletal deconditioning as well as motivational factors to improve long-term treatment adherence and clinical efficacy. More clinical research is warranted to establish the efficacy of exercise intervention in a more differentiated approach for Type 2 diabetes subpopulations within different stages of the disease and various levels of co-morbidity.
Literature
1.
Aretaeus (1972) Of Aretaeus, the Cappadocian. Causes and symptoms of chronic disease, Book I, Chapter II ‘ON DIABETES’. In: Francis Adams LLD (ed) The extant works of Aretaeus, The Cappadocian. Digital Hippocrates Collection. A collection of ancient medical texts. Boston Milford House Inc., Milford, p 91 (Republication of the 1856 edition)
2.
Lancereaux E (1880) Le diabete maigre: ses symptomes, son evolution, son prognostie et son traitement. Un. Med Paris 20:205–211
3.
Pincus G, Joslin EP, White P (1934) Age-incidence relations in diabetes mellitus. Am J Med Sci 188:116–121CrossRef
4.
Zimmet P (2000) Globalization, coca-colonization and the chronic disease epidemic: can the Doomsday scenario be averted? J Intern Med 247:301–310PubMedCrossRef
5.
Engelgau MM, Geiss LS, Saaddine JB et al (2004) The evolving diabetes burden in the United States. Ann Intern Med 140:945–950PubMed
6.
Seidell JC (2000) Obesity, insulin resistance and diabetes—a worldwide epidemic. Br J Nutr 83(Suppl 1):S5–S8PubMed
7.
Mokdad AH, Bowman BA, Ford ES, Vinicor F, Marks JS, Koplan JP (2001) The continuing epidemics of obesity and diabetes in the United States. JAMA 286:1195–1200PubMedCrossRef
8.
Sladek R, Rocheleau G, Rung J et al (2007) A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature 445:881–885PubMedCrossRef
9.
Saxena R, Voight BF, Lyssenko V et al (2007) Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science 316:1331–1336PubMedCrossRef
10.
Prokopenko I, Langenberg C, Florez JC et al (2009) Variants in MTNR1B influence fasting glucose levels. Nat Genet 41:77–81PubMedCrossRef
11.
Cauchi S, Meyre D, Durand E et al (2008) Post genome-wide association studies of novel genes associated with type 2 diabetes show gene-gene interaction and high predictive value. PLoS ONE 3:e2031PubMedCrossRef
12.
Sullivan PW, Morrato EH, Ghushchyan V, Wyatt HR, Hill JO (2005) Obesity, inactivity, and the prevalence of diabetes and diabetes-related cardiovascular comorbidities in the US, 2000–2002. Diabetes Care 28:1599–1603PubMedCrossRef
13.
van Hoek M, Dehghan A, Witteman JC et al (2008) Predicting type 2 diabetes based on polymorphisms from genome-wide association studies: a population-based study. Diabetes 57:3122–3128PubMedCrossRef
14.
Lyssenko V, Groop L (2009) Genome-wide association study for type 2 diabetes: clinical applications. Curr Opin Lipidol 20:87–91PubMedCrossRef
15.
16.
World Health Organization Expert Committee (1999) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. World Health Organization, Geneva
17.
WHO/IDF (2006) Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia: report of a WHO/IDF consultation. World Health Organisation, Geneva
18.
Costa B, Vizcaino J, Pinol JL, Cabre JJ, Fuentes CM (2007) Relevance of casual undetected hyperglycemia among high-risk individuals for developing diabetes. Diabetes Res Clin Pract 78:289–292PubMedCrossRef
19.
Manders RJ, Praet SF, Vikstrom MH, Saris WH, van Loon LJ (2009) Protein hydrolysate co-ingestion does not modulate 24 h glycemic control in long-standing type 2 diabetes patients. Eur J Clin Nutr 63:121–126PubMedCrossRef
20.
Praet SF, Manders RJ, Meex RC et al (2006) Glycaemic instability is an underestimated problem in Type II diabetes. Clin Sci (Lond) 111:119–126CrossRef
21.
Ceriello A (2005) Postprandial hyperglycemia and diabetes complications: is it time to treat? Diabetes 54:1–7PubMedCrossRef
22.
23.
Stumvoll M, Goldstein BJ, van Haeften TW (2005) Type 2 diabetes: principles of pathogenesis and therapy. Lancet 365:1333–1346PubMedCrossRef
24.
Perry JR, Mc Carthy MI, Hattersley AT, Zeggini E, Weedon MN, Frayling TM (2009) Interrogating Type 2 diabetes genome-wide association data using a biological pathway-based approach. Diabetes 58:1463–1467PubMedCrossRef
25.
Perseghin G, Ghosh S, Gerow K, Shulman GI (1997) Metabolic defects in lean nondiabetic offspring of NIDDM parents: a cross-sectional study. Diabetes 46:1001–1009PubMedCrossRef
26.
Taylor R (2008) Pathogenesis of type 2 diabetes: tracing the reverse route from cure to cause. Diabetologia 51:1781–1789PubMedCrossRef
27.
Robertson RP, Harmon J, Tran PO, Tanaka Y, Takahashi H (2003) Glucose toxicity in beta-cells: type 2 diabetes, good radicals gone bad, and the glutathione connection. Diabetes 52:581–587PubMedCrossRef
28.
Dubois M, Kerr-Conte J, Gmyr V et al (2004) Non-esterified fatty acids are deleterious for human pancreatic islet function at physiological glucose concentration. Diabetologia 47:463–469PubMedCrossRef
29.
Hull RL, Westermark GT, Westermark P, Kahn SE (2004) Islet amyloid: a critical entity in the pathogenesis of type 2 diabetes. J Clin Endocrinol Metab 89:3629–3643PubMedCrossRef
30.
Kahn SE, Haffner SM, Heise MA et al (2006) Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355:2427–2443PubMedCrossRef
31.
Holst JJ (2006) Glucagon-like peptide-1: from extract to agent. The Claude Bernard lecture, 2005. Diabetologia 49:253–260PubMedCrossRef
32.
Drucker DJ, Nauck MA (2006) The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368:1696–1705PubMedCrossRef
33.
D’Alessio DA, Denney AM, Hermiller LM et al (2009) Treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin improves fasting islet-cell function in subjects with type 2 diabetes. J Clin Endocrinol Metab 94:81–88PubMedCrossRef
34.
Rosenstock J, Foley JE, Rendell M et al (2008) Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance. Diabetes Care 31:30–35PubMedCrossRef
35.
Ahren B, Schweizer A, Dejager S et al (2009) Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with Type 2 diabetes. J Clin Endocrinol Metab 94:1236–1243PubMedCrossRef
36.
Ferrannini E, Fonseca V, Zinman B et al (2009) Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes Obes Metab 11:157–166PubMedCrossRef
37.
Goke B, Hershon K, Kerr D et al (2008) Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naive patients with type 2 diabetes: comparison with metformin. Horm Metab Res 40:892–895PubMedCrossRef
38.
Moretto TJ, Milton DR, Ridge TD et al (2008) Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 30:1448–1460PubMedCrossRef
39.
Hermansen K, Kipnes M, Luo E, Fanurik D, Khatami H, Stein P (2007) Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab 9:733–745PubMedCrossRef
40.
Jenkins DJ, Kendall CW, Augustin LS, Vuksan V (2002) High-complex carbohydrate or lente carbohydrate foods? Am J Med 113(Suppl 9B):30S–37SPubMedCrossRef
41.
Manders RJ, Praet SF, Meex RC et al (2006) Protein hydrolysate/leucine co-ingestion reduces the prevalence of hyperglycemia in type 2 diabetic patients. Diabetes Care 29:2721–2722PubMedCrossRef
42.
Manders RJ, Koopman R, Sluijsmans WE et al (2006) Co-ingestion of a protein hydrolysate with or without additional leucine effectively reduces postprandial blood glucose excursions in Type 2 diabetic men. J Nutr 136:1294–1299PubMed
43.
van Loon LJ, Kruijshoop M, Menheere PP, Wagenmakers AJ, Saris WH, Keizer HA (2003) Amino acid ingestion strongly enhances insulin secretion in patients with long-term type 2 diabetes. Diabetes Care 26:625–630PubMedCrossRef
44.
Frid AH, Nilsson M, Holst JJ, Bjorck IM (2005) Effect of whey on blood glucose and insulin responses to composite breakfast and lunch meals in type 2 diabetic subjects. Am J Clin Nutr 82:69–75PubMed
45.
Nathan DM, Buse JB, Davidson MB et al (2006) Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 29:1963–1972PubMedCrossRef
46.
Kahn SE, Hull RL, Utzschneider KM (2006) Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 444:840–846PubMedCrossRef
47.
Boden G, Chen X (1995) Effects of fat on glucose uptake and utilization in patients with non-insulin-dependent diabetes. J Clin Invest 96:1261–1268PubMedCrossRef
48.
Boden G (1997) Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes 46:3–10PubMedCrossRef
49.
Kabir M, Catalano KJ, Ananthnarayan S et al (2005) Molecular evidence supporting the portal theory: a causative link between visceral adiposity and hepatic insulin resistance. Am J Physiol Endocrinol Metab 288:E454–E461PubMedCrossRef
50.
Petersen KF, Dufour S, Befroy D, Lehrke M, Hendler RE, Shulman GI (2005) Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. Diabetes 54:603–608PubMedCrossRef
51.
Mooney RA, Senn J, Cameron S et al (2001) Suppressors of cytokine signaling-1 and -6 associate with and inhibit the insulin receptor. A potential mechanism for cytokine-mediated insulin resistance. J Biol Chem 276:25889–25893PubMedCrossRef
52.
Perreault M, Marette A (2001) Targeted disruption of inducible nitric oxide synthase protects against obesity-linked insulin resistance in muscle. Nat Med 7:1138–1143PubMedCrossRef
53.
Xu H, Barnes GT, Yang Q et al (2003) Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 112:1821–1830PubMed
54.
Graham TE, Yang Q, Bluher M et al (2006) Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N Engl J Med 354:2552–2563PubMedCrossRef
55.
Yang Q, Graham TE, Mody N et al (2005) Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature 436:356–362PubMedCrossRef
56.
Balagopal P, Graham TE, Kahn BB, Altomare A, Funanage V, George D (2007) Reduction of elevated serum retinol binding protein in obese children by lifestyle intervention: association with subclinical inflammation. J Clin Endocrinol Metab 92:1971–1974PubMedCrossRef
57.
Haider DG, Schindler K, Mittermayer F et al (2007) Effect of rosiglitazone on visfatin and retinol-binding protein-4 plasma concentrations in HIV-positive patients. Clin Pharmacol Ther 81:580–585PubMedCrossRef
58.
Haider DG, Schindler K, Prager G et al (2007) Serum retinol-binding protein 4 is reduced after weight loss in morbidly obese subjects. J Clin Endocrinol Metab 92:1168–1171PubMedCrossRef
59.
Furler SM, Gan SK, Poynten AM, Chisholm DJ, Campbell LV, Kriketos AD (2006) Relationship of adiponectin with insulin sensitivity in humans, independent of lipid availability. Obesity (Silver Spring) 14:228–234CrossRef
60.
Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K (2006) Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 116:1784–1792PubMedCrossRef
61.
Pedersen BK (2006) The anti-inflammatory effect of exercise: its role in diabetes and cardiovascular disease control. Essays Biochem 42:105–117PubMedCrossRef
62.
van Loon LJ, Goodpaster BH (2006) Increased intramuscular lipid storage in the insulin-resistant and endurance-trained state. Pflugers Arch 451:606–616PubMedCrossRef
63.
Larson-Meyer DE, Heilbronn LK, Redman LM et al (2006) Effect of calorie restriction with or without exercise on insulin sensitivity, beta-cell function, fat cell size, and ectopic lipid in overweight subjects. Diabetes Care 29:1337–1344PubMedCrossRef
64.
Bruce CR, Kriketos AD, Cooney GJ, Hawley JA (2004) Disassociation of muscle triglyceride content and insulin sensitivity after exercise training in patients with Type 2 diabetes. Diabetologia 47:23–30PubMedCrossRef
65.
van Loon LJ, Manders RJ, Koopman R et al (2005) Inhibition of adipose tissue lipolysis increases intramuscular lipid use in type 2 diabetic patients. Diabetologia 48:2097–2107PubMedCrossRef
66.
van Loon LJ, Thomason-Hughes M, Constantin-Teodosiu D et al (2005) Inhibition of adipose tissue lipolysis increases intramuscular lipid and glycogen use in vivo in humans. Am J Physiol Endocrinol Metab 289:E482–E493PubMedCrossRef
67.
van Loon LJ, Koopman R, Manders R, van der Weegen W, van Kranenburg GP, Keizer HA (2004) Intramyocellular lipid content in type 2 diabetes patients compared with overweight sedentary men and highly trained endurance athletes. Am J Physiol Endocrinol Metab 287:E558–E565PubMedCrossRef
68.
Boon H, Blaak EE, Saris WH, Keizer HA, Wagenmakers AJ, van Loon LJ (2007) Substrate source utilisation in long-term diagnosed type 2 diabetes patients at rest, and during exercise and subsequent recovery. Diabetologia 50:103–112PubMedCrossRef
69.
Russell AP, Gastaldi G, Bobbioni-Harsch E et al (2003) Lipid peroxidation in skeletal muscle of obese as compared to endurance-trained humans: a case of good vs. bad lipids? FEBS Lett 551:104–106PubMedCrossRef
70.
71.
72.
Ryysy L, Hakkinen AM, Goto T et al (2000) Hepatic fat content and insulin action on free fatty acids and glucose metabolism rather than insulin absorption are associated with insulin requirements during insulin therapy in type 2 diabetic patients. Diabetes 49:749–758PubMedCrossRef
73.
Cai D, Yuan M, Frantz DF et al (2005) Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med 11:183–190PubMedCrossRef
74.
Samuel VT, Liu ZX, Qu X et al (2004) Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J Biol Chem 279:32345–32353PubMedCrossRef
75.
Samuel VT, Liu ZX, Wang A et al (2007) Inhibition of protein kinase Cepsilon prevents hepatic insulin resistance in nonalcoholic fatty liver disease. J Clin Invest 117:739–745PubMedCrossRef
76.
Goldin A, Beckman JA, Schmidt AM, Creager MA (2006) Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation 114:597–605PubMedCrossRef
77.
Schalkwijk CG, Lieuw-a-Fa M, van Hinsbergh VW, Stehouwer CD (2002) Pathophysiological role of Amadori-glycated proteins in diabetic microangiopathy. Semin Vasc Med 2:191–197PubMedCrossRef
78.
Brownlee M (2001) Biochemistry and molecular cell biology of diabetic complications. Nature 414:813–820PubMedCrossRef
79.
Hogan M, Cerami A, Bucala R (1992) Advanced glycosylation endproducts block the antiproliferative effect of nitric oxide. Role in the vascular and renal complications of diabetes mellitus. J Clin Invest 90:1110–1115
80.
Nishikawa T, Edelstein D, Brownlee M (2000) The missing link: a single unifying mechanism for diabetic complications. Kidney Int Suppl 77:S26–S30PubMedCrossRef
81.
Vincent AM, Perrone L, Sullivan KA et al (2007) Receptor for advanced glycation end products activation injures primary sensory neurons via oxidative stress. Endocrinology 148:548–558PubMedCrossRef
82.
Evans JL, Goldfine ID, Maddux BA, Grodsky GM (2002) Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocr Rev 23:599–622PubMedCrossRef
83.
Wada R, Yagihashi S (2005) Role of advanced glycation end products and their receptors in development of diabetic neuropathy. Ann N Y Acad Sci 1043:598–604PubMedCrossRef
84.
Rosen P, Nawroth PP, King G, Moller W, Tritschler HJ, Packer L (2001) The role of oxidative stress in the onset and progression of diabetes and its complications: a summary of a Congress Series sponsored by UNESCO-MCBN, the American Diabetes Association and the German Diabetes Society. Diabetes Metab Res Rev 17:189–212PubMedCrossRef
85.
Da Ros R, Assaloni R, Ceriello A (2005) Molecular targets of diabetic vascular complications and potential new drugs. Curr Drug Targets 6:503–509PubMedCrossRef
86.
Stitt A, Gardiner TA, Alderson NL et al (2002) The AGE inhibitor pyridoxamine inhibits development of retinopathy in experimental diabetes. Diabetes 51:2826–2832PubMedCrossRef
87.
Ji LL (2002) Exercise-induced modulation of antioxidant defense. Ann N Y Acad Sci 959:82–92PubMed
88.
Stoppa GR, Cesquini M, Roman EA, Ogo SH, Torsoni MA (2006) Aminoguanidine prevented impairment of blood antioxidant system in insulin-dependent diabetic rats. Life Sci 78:1352–1361PubMedCrossRef
89.
Saengsirisuwan V, Perez FR, Sloniger JA, Maier T, Henriksen EJ (2004) Interactions of exercise training and alpha-lipoic acid on insulin signaling in skeletal muscle of obese Zucker rats. Am J Physiol Endocrinol Metab 287:E529–E536PubMedCrossRef
90.
Balducci S, Iacobellis G, Parisi L et al (2006) Exercise training can modify the natural history of diabetic peripheral neuropathy. J Diabetes Complications 20:216–223PubMedCrossRef
91.
Ziegler D, Ametov A, Barinov A et al (2006) Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. Diabetes Care 29:2365–2370PubMedCrossRef
92.
Henriksen EJ (2006) Exercise training and the antioxidant alpha-lipoic acid in the treatment of insulin resistance and type 2 diabetes. Free Radic Biol Med 40:3–12PubMedCrossRef
93.
Regensteiner JG, Sippel J, McFarling ET, Wolfel EE, Hiatt WR (1995) Effects of non-insulin-dependent diabetes on oxygen consumption during treadmill exercise. Med Sci Sports Exerc 27:875–881PubMed
94.
Regensteiner JG, Bauer TA, Reusch JE et al (1998) Abnormal oxygen uptake kinetic responses in women with type II diabetes mellitus. J Appl Physiol 85:310–317PubMed
95.
Estacio RO, Wolfel EE, Regensteiner JG et al (1996) Effect of risk factors on exercise capacity in NIDDM. Diabetes 45:79–85PubMedCrossRef
96.
97.
De Feyter HM, van den Broek NM, Praet SF, Nicolay K, van Loon LJ, Prompers JJ (2008) Early or advanced stage type 2 diabetes is not accompanied by in vivo skeletal muscle mitochondrial dysfunction. Eur J Endocrinol 158:643–653PubMedCrossRef
98.
Trenell MI, Hollingsworth KG, Lim EL, Taylor R (2008) Increased daily walking improves lipid oxidation without changes in mitochondrial function in Type 2 diabetes. Diabetes Care 31:1644–1649PubMedCrossRef
99.
Petersen KF, Dufour S, Befroy D, Garcia R, Shulman GI (2004) Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. N Engl J Med 350:664–671PubMedCrossRef
100.
Petersen KF, Befroy D, Dufour S et al (2003) Mitochondrial dysfunction in the elderly: possible role in insulin resistance. Science 300:1140–1142PubMedCrossRef
101.
Kelley DE, He J, Menshikova EV, Ritov VB (2002) Dysfunction of mitochondria in human skeletal muscle in type 2 diabetes. Diabetes 51:2944–2950PubMedCrossRef
102.
Short KR, Nair KS, Stump CS (2004) Impaired mitochondrial activity and insulin-resistant offspring of patients with type 2 diabetes. N Engl J Med 350:2419–2421; author reply 2419–2421
103.
Simoneau JA, Kelley DE (1997) Altered glycolytic and oxidative capacities of skeletal muscle contribute to insulin resistance in NIDDM. J Appl Physiol 83:166–171PubMed
104.
Rabol R, Boushel R, Dela F (2006) Mitochondrial oxidative function and type 2 diabetes. Appl Physiol Nutr Metab 31:675–683PubMedCrossRef
105.
Szendroedi J, Schmid AI, Chmelik M et al (2007) Muscle mitochondrial ATP synthesis and glucose transport/phosphorylation in type 2 diabetes. PLoS Med 4:e154PubMedCrossRef
106.
107.
Schrauwen-Hinderling VB, Kooi ME, Hesselink MK et al (2007) Impaired in vivo mitochondrial function but similar intramyocellular lipid content in patients with type 2 diabetes mellitus and BMI-matched control subjects. Diabetologia 50:113–120PubMedCrossRef
108.
Sirikul B, Gower BA, Hunter GR, Larson-Meyer DE, Newcomer BR (2006) Relationship between insulin sensitivity and in vivo mitochondrial function in skeletal muscle. Am J Physiol Endocrinol Metab 291:E724–E728PubMedCrossRef
109.
Mogensen M, Sahlin K, Fernstrom M et al (2007) Mitochondrial respiration is decreased in skeletal muscle of patients with type 2 diabetes. Diabetes 56:1592–1599PubMedCrossRef
110.
Boushel R, Gnaiger E, Schjerling P, Skovbro M, Kraunsoe R, Dela F (2007) Patients with type 2 diabetes have normal mitochondrial function in skeletal muscle. Diabetologia 50:790–796PubMedCrossRef
111.
Brons C, Jensen CB, Storgaard H et al (2008) Mitochondrial function in skeletal muscle is normal and unrelated to insulin action in young men born with low birth weight. J Clin Endocrinol Metab 93:3885–3892PubMedCrossRef
112.
113.
Porte D Jr, Baskin DG, Schwartz MW (2005) Insulin signaling in the central nervous system: a critical role in metabolic homeostasis and disease from C. elegans to humans. Diabetes 54:1264–1276
114.
Landsberg L (2001) Insulin-mediated sympathetic stimulation: role in the pathogenesis of obesity-related hypertension (or, how insulin affects blood pressure, and why). J Hypertens 19:523–528PubMedCrossRef
115.
Muntzel MS, Anderson EA, Johnson AK, Mark AL (1995) Mechanisms of insulin action on sympathetic nerve activity. Clin Exp Hypertens 17:39–50PubMedCrossRef
116.
Dunbar JC, Lu H (1999) Leptin-induced increase in sympathetic nervous and cardiovascular tone is mediated by proopiomelanocortin (POMC) products. Brain Res Bull 50:215–221PubMedCrossRef
117.
Tentolouris N, Liatis S, Katsilambros N (2006) Sympathetic system activity in obesity and metabolic syndrome. Ann N Y Acad Sci 1083:129–152PubMedCrossRef
118.
Frontoni S, Bracaglia D, Baroni A et al (2003) Early autonomic dysfunction in glucose-tolerant but insulin-resistant offspring of type 2 diabetic patients. Hypertension 41:1223–1227PubMedCrossRef
119.
Vinik AI, Maser RE, Mitchell BD, Freeman R (2003) Diabetic autonomic neuropathy. Diabetes Care 26:1553–1579PubMedCrossRef
120.
Ziegler D, Zentai C, Perz S et al (2006) Selective contribution of diabetes and other cardiovascular risk factors to cardiac autonomic dysfunction in the general population. Exp Clin Endocrinol Diabetes 114:153–159PubMedCrossRef
121.
Nesto RW (2004) Correlation between cardiovascular disease and diabetes mellitus: current concepts. Am J Med 116(Suppl 5A):11S–22SPubMedCrossRef
122.
Spijkerman AM, Henry RM, Dekker JM et al (2004) Prevalence of macrovascular disease amongst type 2 diabetic patients detected by targeted screening and patients newly diagnosed in general practice: the Hoorn Screening Study. J Intern Med 256:429–436PubMedCrossRef
123.
Gerritsen J, Dekker JM, TenVoorde BJ et al (2001) Impaired autonomic function is associated with increased mortality, especially in subjects with diabetes, hypertension, or a history of cardiovascular disease: the Hoorn Study. Diabetes Care 24:1793–1798PubMedCrossRef
124.
Colhoun HM, Betteridge DJ, Durrington PN et al (2004) Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364:685–696PubMedCrossRef
125.
Scott R, O’Brien R, Fulcher G et al (2009) Effects of fenofibrate treatment on cardiovascular disease risk in 9, 795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetes Care 32:493–498PubMedCrossRef
126.
Patel A, MacMahon S, Chalmers J et al (2007) Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 370:829–840PubMedCrossRef
127.
Turner R et al (1998) Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. Br Med J 317:703–713
128.
Skyler JS, Bergenstal R, Bonow RO et al (2009) Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Diabetes Care 32:187–192PubMedCrossRef
129.
Stratton IM, Cull CA, Adler AI, Matthews DR, Neil HA, Holman RR (2006) Additive effects of glycaemia and blood pressure exposure on risk of complications in type 2 diabetes: a prospective observational study (UKPDS 75). Diabetologia 49:1761–1769PubMedCrossRef
130.
UK Prospective Diabetes Study Group U (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837–853CrossRef
131.
Ohkubo Y, Kishikawa H, Araki E et al (1995) Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 28:103–117PubMedCrossRef
132.
Patel A, MacMahon S, Chalmers J et al (2008) Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358:2560–2572PubMedCrossRef
133.
Nissen SE, Wolski K (2007) Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356:2457–2471PubMedCrossRef
134.
Gerstein HC, Miller ME, Byington RP et al (2008) Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358:2545–2559PubMedCrossRef
135.
Duckworth W, Abraira C, Moritz T et al (2009) Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 360:129–139PubMedCrossRef
136.
Pi-Sunyer X, Blackburn G, Brancati FL et al (2007) Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial. Diabetes Care 30:1374–1383PubMedCrossRef
137.
Dunstan DW, Mori TA, Puddey IB et al (1997) The independent and combined effects of aerobic exercise and dietary fish intake on serum lipids and glycemic control in NIDDM. A randomized controlled study. Diabetes Care 20:913–921CrossRef
138.
Lindstrom J, Ilanne-Parikka P, Peltonen M et al (2006) Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet 368:1673–1679PubMedCrossRef
139.
Vanninen E, Uusitupa M, Siitonen O, Laitinen J, Lansimies E (1992) Habitual physical activity, aerobic capacity and metabolic control in patients with newly-diagnosed type 2 (non-insulin-dependent) diabetes mellitus: effect of 1-year diet and exercise intervention. Diabetologia 35:340–346PubMedCrossRef
140.
Torjesen PA, Birkeland KI, Anderssen SA, Hjermann I, Holme I, Urdal P (1997) Lifestyle changes may reverse development of the insulin resistance syndrome. The Oslo Diet and Exercise Study: a randomized trial. Diabetes Care 20:26–31
141.
Kishimoto H, Taniguchi A, Fukushima M et al (2002) Effect of short-term low-intensity exercise on insulin sensitivity, insulin secretion, and glucose and lipid metabolism in non-obese Japanese type 2 diabetic patients. Horm Metab Res 34:27–31PubMedCrossRef
142.
Balducci S, Leonetti F, Di Mario U, Fallucca F (2004) Is a long-term aerobic plus resistance training program feasible for and effective on metabolic profiles in type 2 diabetic patients? Diabetes Care 27:841–842PubMedCrossRef
143.
Pedersen BK, Febbraio MA (2008) Muscle as an endocrine organ: focus on muscle-derived interleukin-6. Physiol Rev 88:1379–1406PubMedCrossRef
144.
Madsen EL, Rissanen A, Bruun JM et al (2008) Weight loss larger than 10% is needed for general improvement of levels of circulating adiponectin and markers of inflammation in obese subjects: a 3-year weight loss study. Eur J Endocrinol 158:179–187PubMedCrossRef
145.
Monzillo LU, Hamdy O, Horton ES et al (2003) Effect of lifestyle modification on adipokine levels in obese subjects with insulin resistance. Obes Res 11:1048–1054PubMedCrossRef
146.
De Feyter HM, Praet SF, van den Broek NM et al (2007) Exercise training improves glycemic control in long-standing, insulin-treated type 2 diabetes patients. Diabetes Care 30:2511–2513PubMedCrossRef
147.
Lambert CP, Wright NR, Finck BN, Villareal DT (2008) Exercise but not diet-induced weight loss decreases skeletal muscle inflammatory gene expression in frail obese elderly persons. J Appl Physiol 105:473–478PubMedCrossRef
148.
Castellano V, Patel DI, White LJ (2008) Cytokine responses to acute and chronic exercise in multiple sclerosis. J Appl Physiol 104:1697–1702PubMedCrossRef
149.
Stewart LK, Flynn MG, Campbell WW et al (2007) The influence of exercise training on inflammatory cytokines and C-reactive protein. Med Sci Sports Exerc 39:1714–1719PubMedCrossRef
150.
Goldhammer E, Tanchilevitch A, Maor I, Beniamini Y, Rosenschein U, Sagiv M (2005) Exercise training modulates cytokines activity in coronary heart disease patients. Int J Cardiol 100:93–99PubMedCrossRef
151.
Mattusch F, Dufaux B, Heine O, Mertens I, Rost R (2000) Reduction of the plasma concentration of C-reactive protein following nine months of endurance training. Int J Sports Med 21:21–24PubMedCrossRef
152.
Starkie R, Ostrowski SR, Jauffred S, Febbraio M, Pedersen BK (2003) Exercise and IL-6 infusion inhibit endotoxin-induced TNF-alpha production in humans. FASEB J 17:884–886PubMed
153.
Thomas DE, Elliott EJ, Naughton GA (2006) Exercise for type 2 diabetes mellitus. Cochrane Database Syst Rev 3:CD002968
154.
Snowling NJ, Hopkins WG (2006) Effects of different modes of exercise training on glucose control and risk factors for complications in type 2 diabetic patients: a meta-analysis. Diabetes Care 29:2518–2527PubMedCrossRef
155.
Halle M, Berg A, Garwers U et al (1999) Influence of 4 weeks’ intervention by exercise and diet on low-density lipoprotein subfractions in obese men with type 2 diabetes. Metabolism 48:641–644PubMedCrossRef
156.
Krook A, Holm I, Pettersson S, Wallberg-Henriksson H (2003) Reduction of risk factors following lifestyle modification programme in subjects with type 2 (non-insulin dependent) diabetes mellitus. Clin Physiol Funct Imaging 23:21–30PubMedCrossRef
157.
Sigal RJ, Kenny GP, Boule NG et al (2007) Effects of aerobic training, resistance training, or both on glycemic control in type 2 diabetes: a randomized trial. Ann Intern Med 147:357–369PubMed
158.
Miller WC, Koceja DM, Hamilton EJ (1997) A meta-analysis of the past 25 years of weight loss research using diet, exercise or diet plus exercise intervention. Int J Obes Relat Metab Disord 21:941–947PubMedCrossRef
159.
Westerterp KR (1999) Obesity and physical activity. Int J Obes Relat Metab Disord 23(Suppl 1):59–64PubMedCrossRef
160.
Hansen D, Dendale P, Berger J, van Loon LJ, Meeusen R (2007) The effects of exercise training on fat-mass loss in obese patients during energy intake restriction. Sports Med 37:31–46PubMedCrossRef
161.
Stich V, Berlan M (2004) Physiological regulation of NEFA availability: lipolysis pathway. Proc Nutr Soc 63:369–374PubMedCrossRef
162.
Paglialunga S, Cianflone K (2007) Regulation of postprandial lipemia: an update on current trends. Appl Physiol Nutr Metab 32:61–75PubMedCrossRef
163.
Stolinski M, Alam S, Jackson NC et al (2008) Effect of 6-month supervised exercise on low-density lipoprotein apolipoprotein B kinetics in patients with type 2 diabetes mellitus. Metabolism 57:1608–1614PubMedCrossRef
164.
Perseghin G, Lattuada G, De Cobelli F et al (2007) Habitual physical activity is associated with intrahepatic fat content in humans. Diabetes Care 30:683–688PubMedCrossRef
165.
Shojaee-Moradie F, Baynes KC, Pentecost C et al (2007) Exercise training reduces fatty acid availability and improves the insulin sensitivity of glucose metabolism. Diabetologia 50:404–413PubMedCrossRef
166.
Tamura Y, Tanaka Y, Sato F et al (2005) Effects of diet and exercise on muscle and liver intracellular lipid contents and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 90:3191–3196PubMedCrossRef
167.
Pastromas S, Terzi AB, Tousoulis D, Koulouris S (2008) Postprandial lipemia: an under-recognized atherogenic factor in patients with diabetes mellitus. Int J Cardiol 7:3–12CrossRef
168.
American Diabetes Association (2009) Standards of medical care in diabetes—2009. Diabetes Care 32(Suppl 1):S13–S61CrossRef
169.
Sigal RJ, Kenny GP, Wasserman DH, Castaneda-Sceppa C, White RD (2006) Physical activity/exercise and type 2 diabetes: a consensus statement from the American Diabetes Association. Diabetes Care 29:1433–1438PubMedCrossRef
170.
American Diabetes Association (2009) Standards of medical care in diabetes—2009. Diabetes Care 32(Suppl 1):S13–S64CrossRef
171.
Devlin JT, Hirshman M, Horton ED, Horton ES (1987) Enhanced peripheral and splanchnic insulin sensitivity in NIDDM men after single bout of exercise. Diabetes 36:434–439PubMedCrossRef
172.
Fenicchia LM, Kanaley JA, Azevedo JL Jr et al (2004) Influence of resistance exercise training on glucose control in women with type 2 diabetes. Metabolism 53:284–289PubMedCrossRef
173.
Koopman R, Manders RJ, Zorenc AH et al (2005) A single session of resistance exercise enhances insulin sensitivity for at least 24 h in healthy men. Eur J Appl Physiol 94:180–187PubMedCrossRef
174.
Garcia-Roves PM, Han DH, Song Z, Jones TE, Hucker KA, Holloszy JO (2003) Prevention of glycogen supercompensation prolongs the increase in muscle GLUT4 after exercise. Am J Physiol Endocrinol Metab 285:E729–E736PubMed
175.
Sriwijitkamol A, Coletta DK, Wajcberg E et al (2007) Effect of acute exercise on AMPK signaling in skeletal muscle of subjects with type 2 diabetes: a time-course and dose-response study. Diabetes 56:836–848PubMedCrossRef
176.
Pencek RR, Fueger PT, Camacho RC, Wasserman DH (2005) Mobilization of glucose from the liver during exercise and replenishment afterward. Can J Appl Physiol 30:292–303PubMed
177.
178.
Dela F, Larsen JJ, Mikines KJ, Ploug T, Petersen LN, Galbo H (1995) Insulin-stimulated muscle glucose clearance in patients with NIDDM. Effects of one-legged physical training. Diabetes 44:1010–1020
179.
Bisquolo VA, Cardoso CG Jr, Ortega KC et al (2005) Previous exercise attenuates muscle sympathetic activity and increases blood flow during acute euglycemic hyperinsulinemia. J Appl Physiol 98:866–871PubMedCrossRef
180.
Mandroukas K, Krotkiewski M, Holm G et al (1986) Muscle adaptations and glucose control after physical training in insulin-dependent diabetes mellitus. Clin Physiol 6:39–52PubMedCrossRef
181.
Henriksson J (1992) Effects of physical training on the metabolism of skeletal muscle. Diabetes Care 15:1701–1711PubMedCrossRef
182.
Cauza E, Hanusch-Enserer U, Strasser B, Kostner K, Dunky A, Haber P (2005) Strength and endurance training lead to different post exercise glucose profiles in diabetic participants using a continuous subcutaneous glucose monitoring system. Eur J Clin Invest 35:745–751PubMedCrossRef
183.
Wagner H, Degerblad M, Thorell A et al (2006) Combined treatment with exercise training and acarbose improves metabolic control and cardiovascular risk factor profile in subjects with mild type 2 diabetes. Diabetes Care 29:1471–1477PubMedCrossRef
184.
Schneider SH, Amorosa LF, Khachadurian AK, Ruderman NB (1984) Studies on the mechanism of improved glucose control during regular exercise in type 2 (non-insulin-dependent) diabetes. Diabetologia 26:355–360PubMedCrossRef
185.
Howorka K, Pumprla J, Haber P, Koller-Strametz J, Mondrzyk J, Schabmann A (1997) Effects of physical training on heart rate variability in diabetic patients with various degrees of cardiovascular autonomic neuropathy. Cardiovasc Res 34:206–214PubMedCrossRef
186.
Farrell PA (2001) Protein metabolism and age: influence of insulin and resistance exercise. Int J Sport Nutr Exerc Metab 11(Suppl):S150–S163
187.
Koopman R, Zorenc AH, Gransier RJ, Cameron-Smith D, van Loon LJ (2006) Increase in S6K1 phosphorylation in human skeletal muscle following resistance exercise occurs mainly in type II muscle fibers. Am J Physiol Endocrinol Metab 290:E1245–E1252PubMedCrossRef
188.
Dunstan DW, Daly RM, Owen N et al (2002) High-intensity resistance training improves glycemic control in older patients with type 2 diabetes. Diabetes Care 25:1729–1736PubMedCrossRef
189.
Castaneda C, Layne JE, Munoz-Orians L et al (2002) A randomized controlled trial of resistance exercise training to improve glycemic control in older adults with type 2 diabetes. Diabetes Care 25:2335–2341PubMedCrossRef
190.
Dela F, Mikines KJ, von Linstow M, Secher NH, Galbo H (1992) Effect of training on insulin-mediated glucose uptake in human muscle. Am J Physiol 263:E1134–E1143PubMed
191.
Kahn SE, Larson VG, Beard JC et al (1990) Effect of exercise on insulin action, glucose tolerance, and insulin secretion in aging. Am J Physiol 258:E937–E943PubMed
192.
Dela F, Ploug T, Handberg A et al (1994) Physical training increases muscle GLUT4 protein and mRNA in patients with NIDDM. Diabetes 43:862–865PubMedCrossRef
193.
Perseghin G, Price TB, Petersen KF et al (1996) Increased glucose transport-phosphorylation and muscle glycogen synthesis after exercise training in insulin-resistant subjects. N Engl J Med 335:1357–1362PubMedCrossRef
194.
Rogers MA, Yamamoto C, Hagberg JM, Martin WH III, Ehsani AA, Holloszy JO (1988) Effect of 6 d of exercise training on responses to maximal and sub-maximal exercise in middle-aged men. Med Sci Sports Exerc 20:260–264PubMedCrossRef
195.
Maiorana A, O’Driscoll G, Taylor R, Green D (2003) Exercise and the nitric oxide vasodilator system. Sports Med 33:1013–1035PubMedCrossRef
196.
Segal KR, Edano A, Abalos A et al (1991) Effect of exercise training on insulin sensitivity and glucose metabolism in lean, obese, and diabetic men. J Appl Physiol 71:2402–2411PubMed
197.
Bruce CR, Hawley JA (2004) Improvements in insulin resistance with aerobic exercise training: a lipocentric approach. Med Sci Sports Exerc 36:1196–1201PubMed
198.
Holten MK, Zacho M, Gaster M, Juel C, Wojtaszewski JF, Dela F (2004) Strength training increases insulin-mediated glucose uptake, GLUT4 content, and insulin signaling in skeletal muscle in patients with type 2 diabetes. Diabetes 53:294–305PubMedCrossRef
199.
Koopman R, Manders RJ, Jonkers RA, Hul GB, Kuipers H, van Loon LJ (2006) Intramyocellular lipid and glycogen content are reduced following resistance exercise in untrained healthy males. Eur J Appl Physiol 96:525–534PubMedCrossRef
200.
Larsen JJ, Dela F, Madsbad S, Galbo H (1999) The effect of intense exercise on postprandial glucose homeostasis in type II diabetic patients. Diabetologia 42:1282–1292PubMedCrossRef
201.
Larsen JJ, Dela F, Kjaer M, Galbo H (1997) The effect of moderate exercise on postprandial glucose homeostasis in NIDDM patients. Diabetologia 40:447–453PubMedCrossRef
202.
Di Loreto C, Fanelli C, Lucidi P et al (2005) Make your diabetic patients walk: long-term impact of different amounts of physical activity on type 2 diabetes. Diabetes Care 28:1295–1302PubMedCrossRef
203.
O’Donovan G, Kearney EM, Nevill AM, Woolf-May K, Bird SR (2005) The effects of 24 weeks of moderate- or high-intensity exercise on insulin resistance. Eur J Appl Physiol 95:522–528PubMedCrossRef
204.
Detournay B, Raccah D, Cadilhac M, Eschwege E (2005) Epidemiology and costs of diabetes treated with insulin in France. Diabetes Metab 31:3–18PubMed
205.
Fang ZY, Sharman J, Prins JB, Marwick TH (2005) Determinants of exercise capacity in patients with type 2 diabetes. Diabetes Care 28:1643–1648PubMedCrossRef
206.
Estacio RO, Regensteiner JG, Wolfel EE, Jeffers B, Dickenson M, Schrier RW (1998) The association between diabetic complications and exercise capacity in NIDDM patients. Diabetes Care 21:291–295PubMedCrossRef
207.
Petrofsky JS, Stewart B, Patterson C, Cole M, Al Malty A, Lee S (2005) Cardiovascular responses and endurance during isometric exercise in patients with Type 2 diabetes compared to control subjects. Med Sci Monit 11:CR470–CR477
208.
Volpato S, Blaum C, Resnick H, Ferrucci L, Fried LP, Guralnik JM (2002) Comorbidities and impairments explaining the association between diabetes and lower extremity disability: the Women’s Health and Aging Study. Diabetes Care 25:678–683PubMedCrossRef
209.
Sayer AA, Dennison EM, Syddall HE, Gilbody HJ, Phillips DI, Cooper C (2005) Type 2 diabetes, muscle strength, and impaired physical function: the tip of the iceberg? Diabetes Care 28:2541–2542PubMedCrossRef
210.
Andersen H, Nielsen S, Mogensen CE, Jakobsen J (2004) Muscle strength in type 2 diabetes. Diabetes 53:1543–1548PubMedCrossRef
211.
Castaneda C, Janssen I (2005) Ethnic comparisons of sarcopenia and obesity in diabetes. Ethn Dis 15:664–670PubMed
212.
Meyer K, Lehmann M, Sunder G, Keul J, Weidemann H (1990) Interval versus continuous exercise training after coronary bypass surgery: a comparison of training-induced acute reactions with respect to the effectiveness of the exercise methods. Clin Cardiol 13:851–861PubMedCrossRef
213.
Meyer K, Samek L, Schwaibold M et al (1997) Interval training in patients with severe chronic heart failure: analysis and recommendations for exercise procedures. Med Sci Sports Exerc 29:306–312PubMed
214.
Festa A, Williams K, D’Agostino R Jr, Wagenknecht LE, Haffner SM (2006) The natural course of beta-cell function in nondiabetic and diabetic individuals: the Insulin Resistance Atherosclerosis Study. Diabetes 55:1114–1120PubMedCrossRef
215.
Camacho RC, Pencek RR, Lacy DB, James FD, Wasserman DH (2004) Suppression of endogenous glucose production by mild hyperinsulinemia during exercise is determined predominantly by portal venous insulin. Diabetes 53:285–293PubMedCrossRef
216.
Sigal RJ, Purdon C, Fisher SJ, Halter JB, Vranic M, Marliss EB (1994) Hyperinsulinemia prevents prolonged hyperglycemia after intense exercise in insulin-dependent diabetic subjects. J Clin Endocrinol Metab 79:1049–1057PubMedCrossRef
217.
Purdon C, Brousson M, Nyveen SL et al (1993) The roles of insulin and catecholamines in the glucoregulatory response during intense exercise and early recovery in insulin-dependent diabetic and control subjects. J Clin Endocrinol Metab 76:566–573PubMedCrossRef
218.
Larsen JJ, Dela F, Madsbad S, Vibe-Petersen J, Galbo H (1999) Interaction of sulfonylureas and exercise on glucose homeostasis in type 2 diabetic patients. Diabetes Care 22:1647–1654PubMedCrossRef
219.
Riddle MC, McDaniel PA, Tive LA (1997) Glipizide-GITS does not increase the hypoglycemic effect of mild exercise during fasting in NIDDM. Diabetes Care 20:992–994PubMedCrossRef
220.
Gulve EA (2008) Exercise and glycemic control in diabetes: benefits, challenges, and adjustments to pharmacotherapy. Phys Ther 88:1297–1321PubMed
221.
Galassetti P, Tate D, Neill RA, Richardson A, Leu SY, Davis SN (2006) Effect of differing antecedent hypoglycemia on counterregulatory responses to exercise in type 1 diabetes. Am J Physiol Endocrinol Metab 290:E1109–E1117PubMedCrossRef
222.
Davis SN, Mann S, Galassetti P et al (2000) Effects of differing durations of antecedent hypoglycemia on counterregulatory responses to subsequent hypoglycemia in normal humans. Diabetes 49:1897–1903PubMedCrossRef
223.
Davis SN, Mann S, Briscoe VJ, Ertl AC, Tate DB (2009) Effects of intensive therapy and antecedent hypoglycemia on counterregulatory responses to hypoglycemia in type 2 diabetes. Diabetes 58:701–709PubMedCrossRef
224.
Ceriello A (2009) Postprandial hyperglycemia and cardiovascular disease: is the HEART2D study the answer? Diabetes Care 32:521–522PubMedCrossRef
225.
226.
Wessels AM, Scheltens P, Barkhof F, Heine RJ (2008) Hyperglycaemia as a determinant of cognitive decline in patients with type 1 diabetes. Eur J Pharmacol 585:88–96PubMedCrossRef
227.
Praet SF, Jonkers RA, Schep G et al (2008) Long-standing, insulin-treated type 2 diabetes patients with complications respond well to short-term resistance and interval exercise training. Eur J Endocrinol 158:163–172PubMedCrossRef
228.
Must A, Spadano J, Coakley EH, Field AE, Colditz G, Dietz WH (1999) The disease burden associated with overweight and obesity. JAMA 282:1523–1529PubMedCrossRef
229.
Sturmer T, Brenner H, Brenner RE, Gunther KP (2001) Non-insulin dependent diabetes mellitus (NIDDM) and patterns of osteoarthritis. The Ulm osteoarthritis study. Scand J Rheumatol 30:169–171
230.
Praet SF, van Rooij ES, Wijtvliet A et al (2008) Brisk walking compared with an individualised medical fitness programme for patients with type 2 diabetes: a randomised controlled trial. Diabetologia 51:736–746PubMedCrossRef
231.
Praet SF, Louwerens JW (2003) The influence of shoe design on plantar pressures in neuropathic feet. Diabetes Care 26:441–445PubMedCrossRef
232.
Perry JE, Ulbrecht JS, Derr JA, Cavanagh PR (1995) The use of running shoes to reduce plantar pressures in patients who have diabetes. J Bone Joint Surg Am 77:1819–1828PubMed
233.
Kastenbauer T, Sokol G, Auinger M, Irsigler K (1998) Running shoes for relief of plantar pressure in diabetic patients. Diabet Med 15:518–522PubMedCrossRef
234.
Kanade RV, van Deursen RW, Harding K, Price P (2006) Walking performance in people with diabetic neuropathy: benefits and threats. Diabetologia 49:1747–1754PubMedCrossRef
235.
Dunstan DW, Vulikh E, Owen N, Jolley D, Shaw J, Zimmet P (2006) Community center-based resistance training for the maintenance of glycemic control in adults with type 2 diabetes. Diabetes Care 29:2586–2591PubMedCrossRef
236.
Dunstan DW, Daly RM, Owen N et al (2005) Home-based resistance training is not sufficient to maintain improved glycemic control following supervised training in older individuals with type 2 diabetes. Diabetes Care 28:3–9PubMedCrossRef
237.
Schneider SH, Khachadurian AK, Amorosa LF, Clemow L, Ruderman NB (1992) Ten-year experience with an exercise-based outpatient life-style modification program in the treatment of diabetes mellitus. Diabetes Care 15:1800–1810PubMedCrossRef
238.
Kirk A, Mutrie N, MacIntyre P, Fisher M (2004) Effects of a 12-month physical activity counselling intervention on glycaemic control and on the status of cardiovascular risk factors in people with Type 2 diabetes. Diabetologia 47:821–832PubMedCrossRef
239.
West DS, DiLillo V, Bursac Z, Gore SA, Greene PG (2007) Motivational interviewing improves weight loss in women with type 2 diabetes. Diabetes Care 30:1081–1087PubMedCrossRef
240.
Tudor-Locke C, Bell RC, Myers AM et al (2004) Controlled outcome evaluation of the First Step Program: a daily physical activity intervention for individuals with type II diabetes. Int J Obes Relat Metab Disord 28:113–119PubMedCrossRef
241.
Kirk A, De Feo P (2007) Strategies to enhance compliance to physical activity for patients with insulin resistance. Appl Physiol Nutr Metab 32:549–556PubMedCrossRef
242.
Van Sluijs EM, Van Poppel MN, Twisk JW, Brug J, Van Mechelen W (2005) The positive effect on determinants of physical activity of a tailored, general practice-based physical activity intervention. Health Educ Res 20:345–356PubMedCrossRef
243.
Thomas N, Alder E, Leese GP (2004) Barriers to physical activity in patients with diabetes. Postgrad Med J 80:287–291PubMedCrossRef
244.
van Sluijs EM, van Poppel MN, Twisk JW, van Mechelen W (2006) Physical activity measurements affected participants’ behavior in a randomized controlled trial. J Clin Epidemiol 59:404–411PubMedCrossRef
245.
Fowler-Brown A, Pignone M, Pletcher M, Tice JA, Sutton SF, Lohr KN (2004) Exercise tolerance testing to screen for coronary heart disease: a systematic review for the technical support for the U.S. Preventive Services Task Force. Ann Intern Med 140:W9–W24PubMed
246.
Fang ZY, Schull-Meade R, Leano R, Mottram PM, Prins JB, Marwick TH (2005) Screening for heart disease in diabetic subjects. Am Heart J 149:349–354PubMedCrossRef
247.
Wackers FJ, Young LH, Inzucchi SE et al (2004) Detection of silent myocardial ischemia in asymptomatic diabetic subjects: the DIAD study. Diabetes Care 27:1954–1961PubMedCrossRef
248.
McAuley PA, Myers JN, Abella JP, Tan SY, Froelicher VF (2007) Exercise capacity and body mass as predictors of mortality among male veterans with type 2 diabetes. Diabetes Care 30:1539–1543PubMedCrossRef
249.
Faglia E, Favales F, Calia P et al (2002) Cardiac events in 735 type 2 diabetic patients who underwent screening for unknown asymptomatic coronary heart disease: 5-year follow-up report from the Milan Study on Atherosclerosis and Diabetes (MiSAD). Diabetes Care 25:2032–2036PubMedCrossRef
250.
Valensi P, Paries J, Brulport-Cerisier V et al (2005) Predictive value of silent myocardial ischemia for cardiac events in diabetic patients: influence of age in a French multicenter study. Diabetes Care 28:2722–2727PubMedCrossRef
251.
Stevens RJ, Kothari V, Adler AI, Stratton IM (2001) The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56). Clin Sci (Lond) 101:671–679CrossRef
252.
Nesto RW, Phillips RT, Kett KG et al (1988) Angina and exertional myocardial ischemia in diabetic and nondiabetic patients: assessment by exercise thallium scintigraphy. Ann Intern Med 108:170–175PubMed
253.
Nesto RW (1999) Screening for asymptomatic coronary artery disease in diabetes. Diabetes Care 22:1393–1395PubMedCrossRef
254.
Cosson E, Paycha F, Paries J et al (2004) Detecting silent coronary stenoses and stratifying cardiac risk in patients with diabetes: ECG stress test or exercise myocardial scintigraphy? Diabet Med 21:342–348PubMedCrossRef
255.
Bax JJ, Bonow RO, Tschope D, Inzucchi SE, Barrett E (2006) The potential of myocardial perfusion scintigraphy for risk stratification of asymptomatic patients with type 2 diabetes. J Am Coll Cardiol 48:754–760PubMedCrossRef
256.
Schmermund A, Mohlenkamp S, Berenbein S et al (2006) Population-based assessment of subclinical coronary atherosclerosis using electron-beam computed tomography. Atherosclerosis 185:177–182PubMedCrossRef
257.
Bacci S, Villella M, Villella A et al (2002) Screening for silent myocardial ischaemia in type 2 diabetic patients with additional atherogenic risk factors: applicability and accuracy of the exercise stress test. Eur J Endocrinol 147:649–654PubMedCrossRef
258.
Elhendy A, Mahoney DW, Khandheria BK, Burger K, Pellikka PA (2003) Prognostic significance of impairment of heart rate response to exercise: impact of left ventricular function and myocardial ischemia. J Am Coll Cardiol 42:823–830PubMedCrossRef
259.
Praet SF, van Loon LJ (2007) Optimizing the therapeutic benefits of exercise in type 2 diabetes. J Appl Physiol 103:1113–1120PubMedCrossRef
260.
Toft UN, Kristoffersen LH, Aadahl M, von Huth Smith L, Pisinger C, Jorgensen T (2007) Diet and exercise intervention in a general population—mediators of participation and adherence: the Inter99 study. Eur J Public Health 17:455–463PubMedCrossRef
261.
Chambliss HO (2005) Exercise duration and intensity in a weight-loss program. Clin J Sport Med 15:113–115PubMedCrossRef
262.
Bautista-Castano I, Molina-Cabrillana J, Montoya-Alonso JA, Serra-Majem L (2004) Variables predictive of adherence to diet and physical activity recommendations in the treatment of obesity and overweight, in a group of Spanish subjects. Int J Obes Relat Metab Disord 28:697–705PubMedCrossRef
263.
Daly J, Sindone AP, Thompson DR, Hancock K, Chang E, Davidson P (2002) Barriers to participation in and adherence to cardiac rehabilitation programs: a critical literature review. Prog Cardiovasc Nurs 17:8–17PubMedCrossRef
264.
Jacobs-van der Bruggen MA, Bos G, Bemelmans WJ, Hoogenveen RT, Vijgen SM, Baan CA (2007) Lifestyle interventions are cost-effective in people with different levels of diabetes risk: results from a modeling study. Diabetes Care 30:128–134PubMedCrossRef
265.
Bemelmans WJ, Wendel-Vos GCW, Bogers RP et al (2008) [Cost effectiveness of exercise and healthy diet counseling among people with increased risk of type II diabetes mellitus. Literature research and model simulations concerning ‘de Beweegkuur’]. RIVM report 260401005, RIVM Bilthoven, The Netherlands, 123 pages, downloaded on March 26th, 2009 from http://​www.​rivm.​nl/​bibliotheek/​rapporten/​260401005.​html
266.
Roux L, Pratt M, Tengs TO et al (2008) Cost effectiveness of community-based physical activity interventions. Am J Prev Med 35:578–588PubMedCrossRef
267.
Gusi N, Reyes MC, Gonzalez-Guerrero JL, Herrera E, Garcia JM (2008) Cost-utility of a walking programme for moderately depressed, obese, or overweight elderly women in primary care: a randomised controlled trial. BMC Public Health 8:231PubMedCrossRef
268.
Wylie-Rosett J, Herman WH, Goldberg RB (2006) Lifestyle intervention to prevent diabetes: intensive and cost effective. Curr Opin Lipidol 17:37–44PubMedCrossRef
269.
Vijgen SM, Hoogendoorn M, Baan CA, de Wit GA, Limburg W, Feenstra TL (2006) Cost effectiveness of preventive interventions in type 2 diabetes mellitus: a systematic literature review. Pharmacoeconomics 24:425–441PubMedCrossRef
270.
Herman WH, Hoerger TJ, Brandle M et al (2005) The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Ann Intern Med 142:323–332PubMed
271.
Ryan DH, Espeland MA, Foster GD et al (2003) Look AHEAD (Action for Health in Diabetes): design and methods for a clinical trial of weight loss for the prevention of cardiovascular disease in type 2 diabetes. Control Clin Trials 24:610–628PubMedCrossRef
272.
Fredriksson J, Anevski D, Almgren P et al (2007) Variation in GYS1 interacts with exercise and gender to predict cardiovascular mortality. PLoS ONE 2:e285PubMedCrossRef
273.
De Moor MH, Posthuma D, Hottenga JJ, Willemsen G, Boomsma DI, De Geus EJ (2007) Genome-wide linkage scan for exercise participation in Dutch sibling pairs. Eur J Hum Genet 15:1252–1259PubMedCrossRef
Metadata
Title
Exercise therapy in Type 2 diabetes
Authors
Stephan F. E. Praet
Luc J. C. van Loon
Publication date
01-12-2009
Publisher
Springer Milan
Published in
Acta Diabetologica / Issue 4/2009
Print ISSN: 0940-5429
Electronic ISSN: 1432-5233
DOI
https://doi.org/10.1007/s00592-009-0129-0

Other articles of this Issue 4/2009

Acta Diabetologica 4/2009 Go to the issue

Review Article

Diabetes, vascular complications and antiplatelet therapy: open problems

Original Article

Alterations in l-arginine and inflammatory markers in type 2 diabetic patients with and without microalbuminuria

Original Article

Effects of diabetes and elevated glucose on nitrergic relaxations in the isolated duodenum of the rat

Original Article

Glycaemic profile characteristics and frequency of impaired awareness of hypoglycaemia in subjects with T1D and repeated hypoglycaemic events

Original Article

Circulating asymmetric dimethylarginine, endothelin-1 and cell adhesion molecules in women with gestational diabetes

Announcement

G.B. Morgagni Prizes 2010
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits